IL145895A0 - Modulation of excitable tissue function by peripherally administered erythropoietin - Google Patents
Modulation of excitable tissue function by peripherally administered erythropoietinInfo
- Publication number
- IL145895A0 IL145895A0 IL14589500A IL14589500A IL145895A0 IL 145895 A0 IL145895 A0 IL 145895A0 IL 14589500 A IL14589500 A IL 14589500A IL 14589500 A IL14589500 A IL 14589500A IL 145895 A0 IL145895 A0 IL 145895A0
- Authority
- IL
- Israel
- Prior art keywords
- modulation
- tissue function
- excitable tissue
- peripherally administered
- administered erythropoietin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29093899A | 1999-04-13 | 1999-04-13 | |
US54722000A | 2000-04-11 | 2000-04-11 | |
PCT/US2000/010019 WO2000061164A1 (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145895A0 true IL145895A0 (en) | 2002-07-25 |
Family
ID=26966493
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14589500A IL145895A0 (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin |
IL145895A IL145895A (en) | 1999-04-13 | 2001-10-11 | Modulation of excitable tissue function by peripherally administered erythropoietin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL145895A IL145895A (en) | 1999-04-13 | 2001-10-11 | Modulation of excitable tissue function by peripherally administered erythropoietin |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1171147A4 (no) |
JP (1) | JP2003520194A (no) |
KR (2) | KR100883232B1 (no) |
CN (1) | CN1607957B (no) |
AU (1) | AU784550B2 (no) |
BG (1) | BG65353B1 (no) |
BR (1) | BR0009737A (no) |
CA (1) | CA2383940A1 (no) |
CR (1) | CR6501A (no) |
CZ (1) | CZ20013695A3 (no) |
EA (1) | EA004766B1 (no) |
HU (1) | HUP0201598A3 (no) |
IL (2) | IL145895A0 (no) |
IS (1) | IS6104A (no) |
MX (1) | MXPA01010177A (no) |
NO (1) | NO20014991L (no) |
NZ (4) | NZ545478A (no) |
PL (1) | PL352223A1 (no) |
SK (1) | SK14412001A3 (no) |
TR (2) | TR200103785T2 (no) |
WO (1) | WO2000061164A1 (no) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7304031B2 (en) | 2001-10-29 | 2007-12-04 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
WO2003089468A1 (en) * | 2002-04-19 | 2003-10-30 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
AU2001267882A1 (en) | 2000-06-30 | 2002-01-14 | Chugai Seiyaku Kabushiki Kaisha | Preventives and remedies for diseases in association with demyelination |
DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
JP2005501801A (ja) * | 2001-02-02 | 2005-01-20 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療 |
US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
ES2297028T3 (es) | 2001-12-07 | 2008-05-01 | Crucell Holland B.V. | Produccion de virus, aislados virales y vacunas. |
US7335490B2 (en) | 2002-01-09 | 2008-02-26 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
KR20060019501A (ko) * | 2002-07-01 | 2006-03-03 | 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 | 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산 |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
RU2341284C2 (ru) * | 2003-03-27 | 2008-12-20 | Янссен Фармацевтика Нв | Применение эритропоэтина в восстановлении после инсульта |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
ATE414144T1 (de) | 2003-05-09 | 2008-11-15 | Crucell Holland Bv | Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon |
DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
PT2371855E (pt) | 2005-08-05 | 2015-11-03 | Araim Pharmaceuticals Inc | Péptidos protetores de tecidos e suas utilizações |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
GB0525540D0 (en) * | 2005-12-15 | 2006-01-25 | Isis Innovation | New treatment |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
CN101062407A (zh) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | ***在预防或治疗视网膜损伤中的用途 |
US8133860B2 (en) * | 2006-07-20 | 2012-03-13 | Rosalind Franklin University Of Medicine And Science | Facilitation of resuscitation from cardiac arrest by erythropoietin |
CN101610782A (zh) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有***或血小板生成素活性的化合物治疗呼吸链紊乱 |
WO2009010107A1 (en) * | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
WO2009094172A2 (en) | 2008-01-22 | 2009-07-30 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
RU2519695C2 (ru) * | 2010-07-21 | 2014-06-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания |
CN111066727B (zh) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
-
2000
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/ja active Pending
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/xx unknown
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/ko not_active IP Right Cessation
- 2000-04-13 NZ NZ560696A patent/NZ560696A/xx not_active IP Right Cessation
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/es active IP Right Grant
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/ko not_active IP Right Cessation
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/pt not_active Application Discontinuation
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/sk not_active Application Discontinuation
- 2000-04-13 CN CN008087466A patent/CN1607957B/zh not_active Expired - Lifetime
- 2000-04-13 IL IL14589500A patent/IL145895A0/xx unknown
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 CA CA002383940A patent/CA2383940A1/en not_active Abandoned
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/xx unknown
- 2000-04-13 EA EA200101073A patent/EA004766B1/ru not_active IP Right Cessation
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/en active IP Right Grant
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/cs unknown
- 2000-04-13 EP EP00923344A patent/EP1171147A4/en not_active Ceased
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/hu unknown
- 2000-04-13 PL PL00352223A patent/PL352223A1/xx not_active Application Discontinuation
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
-
2001
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-11 IS IS6104A patent/IS6104A/is unknown
- 2001-10-12 NO NO20014991A patent/NO20014991L/no not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/bg unknown
- 2001-11-13 CR CR6501A patent/CR6501A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145895A0 (en) | Modulation of excitable tissue function by peripherally administered erythropoietin | |
GB2357774B (en) | Biioabsorbable cyanoacrylate tissue adhesives | |
AU2560099A (en) | Single-use syringe | |
AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
PL351261A1 (en) | Derivatives of indigoid bisindoles | |
AU7362400A (en) | Occlusion of tubular anatomical structures by energy application | |
HK1043369B (zh) | 調製活細胞核接受體PPARγ活動的化合物 | |
AU2492000A (en) | Implantable neuro-stimulator | |
AU6506698A (en) | Tissue implant | |
PL350854A1 (en) | Intermittent substitutive hormonoal therapy with low doswe of oestrogen | |
ZA200107122B (en) | Treatment of acne using lipoic acid. | |
GB0001140D0 (en) | Microgradient intensity modulating multi-leaf collimator r | |
AU7960800A (en) | X-ray generator of open type | |
AU6115400A (en) | Antisense modulation of mekk5 expression | |
AU7876900A (en) | Antisense modulation of fra-1 expression | |
AU3766700A (en) | Human tumor necrosis factor receptor-like 2 | |
AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
AU6092900A (en) | Animals comprising human hepatocellular tissue | |
AU1878201A (en) | Composition for the treatment of damaged tissue | |
AU2410600A (en) | Antisense modulation of g-alpha-i3 expression | |
AU2501200A (en) | Human peptidases | |
AU1921100A (en) | Antisense modulation of smad4 expression | |
AU5394300A (en) | Tissue engineering |